Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.52 |
| ▸ | CDK4 | P11802 | 4/20 | 0.52 |
| ▸ | CCND1 | P24385 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8530694 | 0.84 | KMT2A (0.58) | KMT2AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL2404374 | 0.82 | KMT2A (0.55) | KMT2AHTR2AHTR2CGRIN2BCDK4 | |
| SCHEMBL9701534 | 0.81 | KMT2A (0.71) | KMT2AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL30074152 | 0.81 | KMT2A (0.71) | KMT2AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL12605548 | 0.80 | KMT2A (0.59) | KMT2AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL6192195 | 0.79 | HDAC8 (0.58) | KMT2AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL13315361 | 0.79 | KMT2A (0.55) | KMT2AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL29420405 | 0.79 | KMT2A (1.00) | KMT2ACDK4CCND1LMNAMAPK1 | |
| SCHEMBL1598786 | 0.79 | KMT2A (1.00) | KMT2ACDK4CCND1LMNAMAPK1 | |
| SCHEMBL3354522 | 0.78 | GRIN2B (0.45) | GRIN2BNTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | KMT2A 542/4885HTR2A 5/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.